The central nervous system

Phase III ADAURA study reveals promising results for patients with non-small cell lung cancer

Recently published results from the phase III ADAURA study reveal that osimertinib provided a 5.5-year median disease-free survival in the postsurgical treatment of patients with EGFR-mutated lung cancer, and nearly three out of four patients treated with adjuvant osimertinib were disease-free after four years. The new results also indicated that the use of osimertinib reduced […]

Scroll to top